argenx Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
argenx wird ein jährliches Gewinn- und Umsatzwachstum von 21.6% bzw. 16.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 20.4% betragen.
Wichtige Informationen
21.6%
Wachstumsrate der Gewinne
21.11%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 21.0% |
| Wachstumsrate der Einnahmen | 16.9% |
| Zukünftige Eigenkapitalrendite | 20.44% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 18 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.
Narrativ-Update • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Narrativ-Update • Apr 15
ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power
Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.Narrativ-Update • Apr 01
ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.Narrativ-Update • Mar 17
ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.Narrativ-Update • Mar 03
ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential
The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.Narrativ-Update • Feb 17
ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside
Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
Narrativ-Update • Feb 03
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.Narrativ-Update • Jan 20
ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing
Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.Narrativ-Update • Jan 06
ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks
Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.Narrativ-Update • Dec 15
ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks
Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.Narrativ-Update • Nov 30
ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations
Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.Narrativ-Update • Nov 16
ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm
Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.Narrativ-Update • Nov 02
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.Narrativ-Update • Sep 25
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.Narrativ-Update • Aug 29
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.Narrativ-Update • Aug 06
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.Analyseartikel • Aug 01
What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You
argenx SE ( EBR:ARGX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...Analyseartikel • Jun 30
We Think argenx (EBR:ARGX) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • May 21
We Take A Look At Whether argenx SE's (EBR:ARGX) CEO May Be Underpaid
Key Insights argenx's Annual General Meeting to take place on 27th of May CEO Tim Van Hauwermeiren's total compensation...
Neues Narrativ • Apr 27
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 8,537 | 2,924 | 3,208 | N/A | 22 |
| 12/31/2027 | 7,215 | 2,416 | 3,051 | N/A | 30 |
| 12/31/2026 | 5,930 | 1,757 | 2,552 | N/A | 30 |
| 3/31/2026 | 4,742 | 1,489 | N/A | N/A | N/A |
| 12/31/2025 | 4,236 | 1,292 | 574 | 685 | N/A |
| 9/30/2025 | 3,683 | 1,533 | N/A | N/A | N/A |
| 6/30/2025 | 3,121 | 1,280 | 309 | 404 | N/A |
| 3/31/2025 | 2,643 | 1,064 | N/A | N/A | N/A |
| 12/31/2024 | 2,248 | 833 | -151 | -83 | N/A |
| 9/30/2024 | 1,909 | -40 | N/A | N/A | N/A |
| 6/30/2024 | 1,660 | -204 | -325 | -260 | N/A |
| 3/31/2024 | 1,451 | -328 | N/A | N/A | N/A |
| 12/31/2023 | 1,269 | -295 | -464 | -420 | N/A |
| 9/30/2023 | 1,029 | -234 | N/A | N/A | N/A |
| 6/30/2023 | 835 | -397 | -758 | -654 | N/A |
| 3/31/2023 | 639 | -511 | N/A | N/A | N/A |
| 12/31/2022 | 441 | -710 | -967 | -863 | N/A |
| 9/30/2022 | 286 | -909 | N/A | N/A | N/A |
| 6/30/2022 | 146 | -907 | -874 | -876 | N/A |
| 3/31/2022 | 381 | -595 | N/A | N/A | N/A |
| 12/31/2021 | 528 | -408 | -728 | -607 | N/A |
| 9/30/2021 | 510 | -373 | N/A | N/A | N/A |
| 6/30/2021 | 526 | -319 | -601 | -474 | N/A |
| 3/31/2021 | 206 | -573 | N/A | N/A | N/A |
| 12/31/2020 | 62 | -608 | -404 | -398 | N/A |
| 9/30/2020 | 75 | -535 | N/A | N/A | N/A |
| 6/30/2020 | 70 | -359 | -263 | -255 | N/A |
| 3/31/2020 | 73 | -275 | N/A | N/A | N/A |
| 12/31/2019 | 93 | -181 | N/A | 152 | N/A |
| 9/30/2019 | 72 | -109 | N/A | N/A | N/A |
| 6/30/2019 | 68 | -104 | N/A | 230 | N/A |
| 3/31/2019 | 70 | -47 | N/A | N/A | N/A |
| 12/31/2018 | 33 | -76 | N/A | -62 | N/A |
| 9/30/2018 | 41 | -56 | N/A | N/A | N/A |
| 6/30/2018 | 44 | -47 | N/A | -57 | N/A |
| 3/31/2018 | 50 | -46 | N/A | N/A | N/A |
| 12/31/2017 | 49 | -34 | N/A | -44 | N/A |
| 9/30/2017 | 42 | -30 | N/A | N/A | N/A |
| 6/30/2017 | 39 | -25 | N/A | -31 | N/A |
| 3/31/2017 | 23 | -29 | N/A | N/A | N/A |
| 12/31/2016 | 18 | -22 | N/A | 11 | N/A |
| 9/30/2016 | 17 | -20 | N/A | N/A | N/A |
| 6/30/2016 | 14 | -17 | N/A | 16 | N/A |
| 3/31/2016 | 12 | -17 | N/A | N/A | N/A |
| 12/31/2015 | 11 | -17 | N/A | -15 | N/A |
| 9/30/2015 | 10 | -16 | N/A | N/A | N/A |
| 6/30/2015 | 9 | -14 | N/A | -10 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ARGXDas prognostizierte Gewinnwachstum (21.6% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: ARGXDie Erträge des Unternehmens (21.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Belgian (13.8% pro Jahr).
Hohe Wachstumserträge: ARGXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: ARGXDie Einnahmen des Unternehmens (16.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Belgian (6.7% pro Jahr).
Hohe Wachstumseinnahmen: ARGXDie Einnahmen des Unternehmens (16.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ARGXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (20.4%)
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/20 01:55 |
| Aktienkurs zum Tagesende | 2026/05/20 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
argenx SE wird von 55 Analysten beobachtet. 30 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Baird |
| Colleen Kusy | Baird |
| Joel Beatty | Baird |